Postdoctoral Scientist – Vascularized Kidney Organoids; Institute of Human Biology; IHB

At Roche you can show up as yourself, embraced for the unique qualities you bring. Our culture encourages personal expression, open dialogue, and genuine connections, where you are valued, accepted and respected for who you are, allowing you to thrive both personally and professionally. This is how we aim to prevent, stop and cure diseases and ensure everyone has access to healthcare today and for generations to come.

Join Roche, where every voice matters.

The Institute of Human Biology (IHB), embedded within Roche's Pharma Research and Early Development (pRED) Division, is a leading research institute focused on accelerating the development of transformative medicines. It specializes in developing novel and robust human model systems that functionally resemble human physiology and disease. By bridging the gap between academic discovery and industrial application, IHB facilitates the rapid translation of groundbreaking science into patient-focused solutions.

As part of a newly funded IHB fellowship, you will drive an ambitious research program at the interface of organoid biology, vascular biology, and bioengineering, with the goal of creating translationally relevant systems for drug discovery and safety. In this role, you will define innovative approaches to uncover the biological principles of vascular-parenchymal interaction in the context of kidney development, ultimately helping to establish a new class of human model systems through the following responsibilities:

• Drive the development of vascularized iPSC-derived kidney organoids, with a focus on tissue specification and maturation
• Develop and optimize engineered culture systems to enable vascular perfusion and promote kidney organoid maturation
• Work closely with stem cell biologists to dissect nephron maturation and cell-cell communication
• Translate biological insights into functional, predictive models relevant for human kidney safety

A scientist with a PhD and a strong track record in iPSC-derived 3D tissue models or organoids. To qualify for this early-career position, you must have completed your doctoral studies within the last three years prior to the start date. Scientifically ambitious, with the ability to drive new concepts rather than follow established protocols Experience in bioengineering and/or microfluidics is desirable Ideally with a strong background in developmental biology, with expertise in kidney, vascular, or related organ systems

You will be embedded in a highly interdisciplinary ecosystem at IHB, working with leading experts in bioengineering, stem cell biology, and computational analysis, and closely connected to Roche's drug discovery and safety teams. This is a unique opportunity to define how human kidney models are built and used in the future-from fundamental biology to direct impact on drug development.

Roche is an Equal Opportunity Employer.

A healthier future drives us to innovate. Together, more than 100'000 employees across the globe are dedicated to advance science, ensuring everyone has access to healthcare today and for generations to come. Our efforts result in more than 26 million people treated with our medicines and over 30 billion tests conducted using our Diagnostics products. We empower each other to explore new possibilities, foster creativity, and keep our ambitions high, so we can deliver life-changing healthcare solutions that make a global impact.

Let's build a healthier future, together. We believe it's urgent to deliver medical solutions right now - even as we develop innovations for the future. We are passionate about transforming patients' lives. We are courageous in both decision and action. And we believe that good business means a better world. That is why we come to work each day. We commit ourselves to scientific rigor, unassailable ethics, and access to medical innovations for all.

We do this today to build a better tomorrow. We are proud of who we are, what we do, and how we do it. We are many, working as one across functions, across companies, and across the world. We are Roche.